Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

$2.8 billion U.S. peripheral vascular device market to grow to over $5.3 billion by 2016

According to a new report by iData Research, the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers of this market, particularly in the stent-graft and peripheral vascular stent segments. These markets are both expected to exceed $1 billion by 2016.

11 May 2010

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

EntreMed, Inc., today announced the addition of Dana Farber/Harvard Cancer Center (DF/HCC) to the Phase 2 multi-center study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Platinum Resistant Ovarian Cancer." Ursula Matulonis, M.D., Associate Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School, will serve as principal investigator.

11 May 2010

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

Sosei Group Corporation announce the commencement of the Phase III clinical programme by Novartis, with QVA149, a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of chronic obstructive pulmonary disease (COPD). The start of Phase III triggers a $7.5m milestone payment to Sosei.

10 May 2010

GSK participates in FDA advisory committee's rotavirus vaccine meeting

GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.

10 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

10 May 2010

Xience V sales out-performing Promus in Japanese drug-eluting stent market: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, when Abbott Vascular's Xience V and Boston Scientific's Promus entered the Japanese drug-eluting stent market in Q1 2010, both companies picked up share from competitors Medtronic and Cordis.

6 May 2010

Micrus Endovascular reports 24% increase in fourth-quarter neurovascular revenues

Micrus Endovascular Corporation today reported financial results for the three and 12 months ended March 31, 2010 and introduced fiscal 2011 financial guidance.

6 May 2010

Abbott's SPIRIT IV trial results published in The New England Journal of Medicine

Findings from Abbott's SPIRIT IV trial, one of the largest randomized clinical trials comparing two drug eluting stents, with 3,690 U.S.-based patients, were published today in The New England Journal of Medicine.

6 May 2010

Cohera Medical reports top-line results from Tissuglu clinical trial

Cohera Medical, Inc.® today announced that top-line clinical study results demonstrate the safety and preliminary effectiveness of the company's lead surgical adhesive product, TissuGlu®.

6 May 2010

CSI fiscal third-quarter revenue increases 9% to $16.5 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2010.

6 May 2010

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Pharmacyclics, Inc. today reported financial results for its third quarter ended March 31, 2010.

6 May 2010

Watson Laboratories files raloxifene hydrochloride tablet ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a raloxifene hydrochloride tablet. Watson's raloxifene hydrochloride tablet is a generic version of Eli Lilly's EVISTA®.

6 May 2010

Jazz Pharmaceuticals reports 59% increase in first-quarter 2010 revenue

Jazz Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2010 and updated guidance for sales and expenses for 2010.

6 May 2010

LightLab Imaging granted FDA clearance for C7-XR Imaging System and C7 Dragonfly Imaging Catheter

LightLab Imaging, Inc., the pioneer and leader in the development of Optical Coherence Tomography (OCT) technology for vascular and other imaging applications, has received clearance from the U.S. Food and Drug Administration (FDA) for the C7-XR Imaging System and companion C7 Dragonfly Imaging Catheter.

5 May 2010

Cardiovascular specialists demonstrate effectiveness of using stents to repair aortas

A UC Davis team of cardiovascular specialists has demonstrated the effectiveness of using stents -- as compared to traditional open-chest surgery -- to repair aortas that are torn as the result of accidents. The researchers will present their findings at the American Association for Thoracic Surgery Aortic Symposium 2010, which takes place April 29-30 in New York City.

4 May 2010

FDA grants marketing clearance for Immucor's NEO automated blood bank instrument

Immucor, Inc., a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that its fourth generation automated instrument, NEO™, has been cleared for marketing in the U.S. by the Food and Drug Administration ("FDA"). NEO is a fully automated blood bank instrument designed to meet the needs of high volume laboratories.

30 Apr 2010

Boston Scientific to present multiple clinical abstracts on its endoscopy products at DDW 2010

Boston Scientific Corporation today announced that multiple clinical abstracts examining the diagnostic and therapeutic utility of its SpyGlass Direct Visualization System, Radial Jaw 4 Biopsy Forceps and WallFlex Duodenal Stent will be presented at Digestive Disease Week, May 1 – 5 in New Orleans.

30 Apr 2010

TenX Biopharma signs Clinical Trial Agreement with NCI

TenX Biopharma, Inc., announced today it has signed a Clinical Trial Agreement with the National Cancer Institute to conduct an investigator sponsored Phase II clinical trial.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

Stent News and Research

Further Reading

$2.8 billion U.S. peripheral vascular device market to grow to over $5.3 billion by 2016

EntreMed adds DF/HCC hospitals to Phase 2 study of ENMD-2076 for platinum resistant ovarian cancer

Initiation of QVA149 Phase III clinical programme by Novartis triggers $7.5M milestone payment to Sosei

GSK participates in FDA advisory committee's rotavirus vaccine meeting

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Xience V sales out-performing Promus in Japanese drug-eluting stent market: MRG

Micrus Endovascular reports 24% increase in fourth-quarter neurovascular revenues

Abbott's SPIRIT IV trial results published in The New England Journal of Medicine

Cohera Medical reports top-line results from Tissuglu clinical trial

CSI fiscal third-quarter revenue increases 9% to $16.5 million

Pharmacyclics reports total GAAP revenues of $2.1 million for third-quarter fiscal 2010

Watson Laboratories files raloxifene hydrochloride tablet ANDA

Jazz Pharmaceuticals reports 59% increase in first-quarter 2010 revenue

LightLab Imaging granted FDA clearance for C7-XR Imaging System and C7 Dragonfly Imaging Catheter

Cardiovascular specialists demonstrate effectiveness of using stents to repair aortas

FDA grants marketing clearance for Immucor's NEO automated blood bank instrument

Boston Scientific to present multiple clinical abstracts on its endoscopy products at DDW 2010

TenX Biopharma signs Clinical Trial Agreement with NCI

PROVENGE receives FDA approval for treatment of CRPC

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News